Heat Biologics (HTBX) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Heat Biologics (NASDAQ:HTBX) in a research note published on Tuesday morning. The firm issued a buy rating and a $6.00 target price on the biopharmaceutical company’s stock.

Separately, ValuEngine upgraded Heat Biologics from a sell rating to a hold rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $14.25.

Shares of Heat Biologics opened at $2.26 on Tuesday, according to MarketBeat Ratings. Heat Biologics has a 52 week low of $1.09 and a 52 week high of $7.90.

Heat Biologics (NASDAQ:HTBX) last announced its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.05). The firm had revenue of $0.75 million during the quarter. Heat Biologics had a negative net margin of 543.30% and a negative return on equity of 182.19%.

A hedge fund recently raised its stake in Heat Biologics stock. Sabby Management LLC lifted its stake in Heat Biologics Inc (NASDAQ:HTBX) by 52.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,615,123 shares of the biopharmaceutical company’s stock after purchasing an additional 902,642 shares during the period. Sabby Management LLC owned 62.26% of Heat Biologics worth $1,001,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.89% of the company’s stock.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply